Lupin lines up 50 generic products for Australia as patent expiries loom
This article was originally published in Scrip
Executive Summary
Lupin is scaling up its operations in the Australian market, beefing up its sales force and product portfolio there ahead of an anticipated flurry of patent expiries for leading prescription products.